DK2894165T3 - Fremgangsmåder og sammensætninger til behandling af komplementforbundne forstyrrelser - Google Patents

Fremgangsmåder og sammensætninger til behandling af komplementforbundne forstyrrelser Download PDF

Info

Publication number
DK2894165T3
DK2894165T3 DK15152757.9T DK15152757T DK2894165T3 DK 2894165 T3 DK2894165 T3 DK 2894165T3 DK 15152757 T DK15152757 T DK 15152757T DK 2894165 T3 DK2894165 T3 DK 2894165T3
Authority
DK
Denmark
Prior art keywords
compositions
methods
related disorders
treating complement
complement
Prior art date
Application number
DK15152757.9T
Other languages
English (en)
Other versions
DK2894165T5 (da
Inventor
Russell P Rother
Camille Bedrosian
Stephen P Squinto
Leonard Bell
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42153320&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2894165(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Application granted granted Critical
Publication of DK2894165T3 publication Critical patent/DK2894165T3/da
Publication of DK2894165T5 publication Critical patent/DK2894165T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK15152757.9T 2008-11-10 2009-11-10 Fremgangsmåder og sammensætninger til behandling af komplementforbundne forstyrrelser DK2894165T5 (da)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US19880308P 2008-11-10 2008-11-10
US19956908P 2008-11-18 2008-11-18
US19956208P 2008-11-18 2008-11-18
US19956308P 2008-11-18 2008-11-18
US19976408P 2008-11-19 2008-11-19
US20063508P 2008-12-01 2008-12-01
US20063408P 2008-12-01 2008-12-01
US20064008P 2008-12-01 2008-12-01
US18178809P 2009-05-28 2009-05-28
US22804709P 2009-07-23 2009-07-23
EP09825611A EP2352517A4 (en) 2008-11-10 2009-11-10 METHOD AND COMPOSITIONS FOR TREATING COMPLEMENT ASSOCIATED ILLNESSES

Publications (2)

Publication Number Publication Date
DK2894165T3 true DK2894165T3 (da) 2023-03-20
DK2894165T5 DK2894165T5 (da) 2024-10-14

Family

ID=42153320

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15152757.9T DK2894165T5 (da) 2008-11-10 2009-11-10 Fremgangsmåder og sammensætninger til behandling af komplementforbundne forstyrrelser

Country Status (21)

Country Link
US (9) US9447176B2 (da)
EP (6) EP2894165B1 (da)
JP (8) JP6223659B2 (da)
KR (1) KR20110094029A (da)
CN (3) CN102271703B (da)
AU (1) AU2009313203B2 (da)
BR (1) BRPI0921237A2 (da)
CA (2) CA2742802C (da)
DK (1) DK2894165T5 (da)
ES (1) ES2940466T3 (da)
FI (1) FI2894165T3 (da)
HR (1) HRP20230167T1 (da)
HU (1) HUE061548T2 (da)
LT (1) LT2894165T (da)
NZ (3) NZ606825A (da)
PL (1) PL2894165T3 (da)
PT (1) PT2894165T (da)
RS (1) RS64039B1 (da)
SI (1) SI2894165T1 (da)
SM (1) SMT202300082T1 (da)
WO (1) WO2010054403A1 (da)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
SI3028716T1 (sl) 2006-10-10 2021-01-29 Regenesance B.V. Komplementarna inhibicija za izboljšano regeneracijo živcev
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
EP2275443B1 (en) 2008-04-11 2015-12-02 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US9447176B2 (en) * 2008-11-10 2016-09-20 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
SMT202200074T1 (it) 2008-12-22 2022-03-21 Chemocentryx Inc Antagonisti di c5ar
KR20120105405A (ko) * 2009-06-23 2012-09-25 알렉시온 파마슈티칼스, 인코포레이티드 보체 단백질에 결합하는 이중특이적 항체
CA2791962A1 (en) * 2010-03-01 2011-09-09 Alexion Pharmaceuticals, Inc. Methods and compositions for treating degos' disease
JP6022441B2 (ja) 2010-04-30 2016-11-09 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗Ｃ５ａ抗体およびその抗体の使用のための方法
HRP20171176T1 (hr) 2010-06-24 2017-10-06 Chemocentryx, Inc. C5ar antagonisti
CN103237557A (zh) * 2010-09-15 2013-08-07 赛尔戴克斯治疗公司 用可溶性I型补体受体(sCR1)治疗慢性肾病
TWI654204B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
US20150166676A1 (en) * 2011-04-08 2015-06-18 Omeros Corporation Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
CN107638565B (zh) 2011-04-08 2021-12-21 莱斯特大学 用于治疗与masp-2依赖性补体活化相关的状况的方法
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP2723361B1 (en) 2011-06-22 2019-10-30 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
RS58503B1 (sr) 2012-02-20 2019-04-30 Swedish Orphan Biovitrum Ab Publ Polipeptidi koji se vezuju za humani komplement c5
WO2013137912A2 (en) * 2012-03-16 2013-09-19 Alexion Pharmaceuticals, Inc. Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor
EP2861246B1 (en) * 2012-06-18 2021-01-20 Omeros Corporation Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders
CN104870474B (zh) * 2012-10-04 2019-03-12 诺沃姆德治疗公司 用于治疗溶血性疾病的旁路途径特异性抗体
WO2014066744A2 (en) 2012-10-25 2014-05-01 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
PL2914291T3 (pl) 2012-11-02 2022-10-03 Bioverativ Usa Inc. Przeciwciała anty-C1s dopełniacza i ich zastosowania
WO2014078622A1 (en) * 2012-11-15 2014-05-22 The Brigham And Women's Hospital, Inc. Method and system for diagnosing and treating preeclampsia
WO2014110438A1 (en) * 2013-01-11 2014-07-17 Alexion Pharmaceuticals, Inc. Compounds and methods related to the c5d domain of complement component c5
BR112015018438A2 (pt) * 2013-01-31 2017-07-18 Seoul Nat Univ R&Db Foundation anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento
ME03043B (me) 2013-03-14 2018-10-20 Alnylam Pharmaceuticals Inc Irnk sastavi komponente komplementa c5 i metode za njihovu upotrebu
JP6373963B2 (ja) * 2013-03-14 2018-08-15 バクスアルタ インコーポレイテッド 移植のためのｈ因子
EP3473272A1 (en) 2013-03-29 2019-04-24 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
SI3011345T1 (sl) 2013-08-07 2017-12-29 Alexion Pharmaceuticals, Inc. Biomarkerski proteini za atipični hemolitični uremični sindrom (ahus)
US20160184391A1 (en) * 2013-08-16 2016-06-30 Alexion Pharmaceuticals, Inc. Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant
US10815296B2 (en) * 2013-09-16 2020-10-27 Children's Hospital Medical Center Methods of treatment of HSCT-associated thrombotic microangiopathy with eculizumab
RS61351B1 (sr) * 2013-10-17 2021-02-26 Omeros Corp Postupci za lečenje stanja udruženih sa aktivacijom komplementa zavisnom od masp-2
CA2931090A1 (en) 2013-12-12 2015-06-18 Alnylam Pharmaceuticals, Inc. Complement component irna compositions and methods of use thereof
AU2015218903B2 (en) * 2014-02-20 2020-10-15 Allergan, Inc. Complement component C5 antibodies
HUE050921T2 (hu) * 2014-02-26 2021-01-28 Allergan Inc C5 komplementkomponens antitestek
NZ711451A (en) * 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
US10155983B2 (en) 2014-03-31 2018-12-18 Machaon Diagnostics, Inc. Method of diagnosis of complement-mediated thrombotic microangiopathies
HUE045646T2 (hu) 2014-06-12 2020-01-28 Ra Pharmaceuticals Inc Komplement aktivitás modulálása
EP3191591A1 (en) * 2014-09-12 2017-07-19 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting complement component c5 and methods of use thereof
EP3682879B1 (en) 2014-09-29 2022-08-03 ChemoCentryx, Inc. Processes and intermediates in the preparation of c5ar antagonists
WO2016081314A1 (en) 2014-11-17 2016-05-26 Alexion Pharmaceuticals, Inc. Risk evaluation and management strategy involving patient follow-ups relating to a complement inhibitor
US20160168237A1 (en) * 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Method for treating a complement mediated disorder caused by an infectious agent in a patient
NZ730607A (en) 2014-12-19 2022-07-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
SG10201710322VA (en) 2014-12-19 2018-02-27 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
CN107428823B (zh) * 2015-01-22 2021-10-26 中外制药株式会社 两种以上抗-c5抗体的组合与使用方法
WO2016123371A1 (en) 2015-01-28 2016-08-04 Ra Pharmaceuticals, Inc. Modulators of complement activity
WO2016125495A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
PL3280440T3 (pl) 2015-04-06 2023-06-19 Bioverativ Usa Inc. Humanizowane przeciwciała anty-c1s i sposoby ich zastosowania
EP3288586A1 (en) * 2015-05-01 2018-03-07 Alexion Pharmaceuticals, Inc. Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of kindney thansplant
EP3307318A4 (en) 2015-06-09 2019-01-16 Children's Hospital Medical Center DOSAGE ALGORITHM FOR COMPLEMENT INHIBITOR
WO2016201301A1 (en) 2015-06-12 2016-12-15 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
US20180243370A1 (en) 2015-09-14 2018-08-30 Children's Hospital Medical Center Methods and compositions for treatment of gaucher disease via modulation of c5a receptor
EP3368073B1 (en) * 2015-10-30 2024-05-15 Alexion Pharmaceuticals, Inc. A method of inhibiting exacerbations of t cell-mediated allograft vasculopathy
EP4218790B1 (en) 2015-12-16 2026-02-18 UCB Holdings, Inc. Modulators of complement activity
AU2016375183B2 (en) * 2015-12-23 2021-01-21 eleva GmbH Polypeptides for inhibiting complement activation
MX2022006069A (es) * 2016-01-14 2023-01-12 Chemocentryx Inc Metodo para tratar glomerulopatia c3.
EP3454902A4 (en) * 2016-05-10 2019-10-09 Annexon, Inc. ANTI-COMPLEMENT FACTOR C4 / C4B ANTIBODIES AND USES THEREOF
AU2017269839A1 (en) * 2016-05-27 2018-11-22 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis
US20190225678A1 (en) * 2016-06-07 2019-07-25 Novartis Ag Anti-c5 antibody for treating patients with complement c5 polymorphism
CN109310760A (zh) * 2016-06-07 2019-02-05 诺华股份有限公司 抗c5抗体给药方案
CN109310759A (zh) * 2016-06-07 2019-02-05 诺华股份有限公司 用于在移植排斥治疗中使用的特斯多鲁单抗
WO2017214518A1 (en) 2016-06-10 2017-12-14 Alnylam Pharmaceuticals, Inc. COMPLETMENT COMPONENT C5 iRNA COMPOSTIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
WO2017218515A1 (en) 2016-06-14 2017-12-21 Regeneron Pharmaceuticals, Inc. Anti-c5 antibodies and uses thereof
BR112019001902A2 (pt) 2016-08-05 2019-07-09 Chugai Seiyaku Kabushiki Kaisha composição para profilaxia ou tratamento de doenças relacionadas à il-8
EP4652926A3 (en) 2016-10-12 2026-03-18 Bioverativ USA Inc. Anti-c1s antibodies and methods of use thereof
WO2018081400A1 (en) 2016-10-27 2018-05-03 Alexion Pharmaceuticals Inc. Assay for c5b-9 deposition in complement-associated disorders
CA3045114A1 (en) 2016-12-07 2018-06-14 Ra Pharmaceuticals, Inc. Modulators of complement activity
CR20190403A (es) 2017-01-31 2019-10-10 Hoffmann La Roche Una composición farmacéutica que comprende un anticuerpo anti-c5 contra una enfermedad relacionada con c5 y un producto de la misma
ES2975416T3 (es) * 2017-02-27 2024-07-05 Regeneron Pharma Modelo humanizado de trastornos renales y hepáticos
BR112019018429A2 (pt) * 2017-03-06 2020-04-14 Univ Pennsylvania anticorpo, métodos para tratar uma doença ou distúrbio mediado pela via do complemento em um indíviduo e para reduzir a atividade de um sistema complemento de um indivíduo, e, célula
WO2018217638A1 (en) * 2017-05-22 2018-11-29 Alexion Pharmaceuticals Inc. Dosage and administration of anti-c5 antibodies for treatment of protein-losing enteropathy in patients
BR112020001703B1 (pt) 2017-07-27 2024-01-02 Alexion Pharmaceuticals, Inc Solução aquosa estável compreendendo um anticorpo anti-c5, método para produção desta solução, uso da mesma para tratar uma condição associada ao complemento e kit terapêutico compreendendo a mesma
US20200262897A1 (en) * 2017-10-04 2020-08-20 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of patients with membranoproliferative glomerulonephritis
EP3700928A1 (en) 2017-10-26 2020-09-02 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus)
US11866701B2 (en) 2017-11-01 2024-01-09 Alnylam Pharmaceuticals, Inc. Complement component C3 iRNA compositions and methods of use thereof
WO2019099786A1 (en) 2017-11-16 2019-05-23 Ophthotech Corporation A method for treating or preventing idiopathic polypoidal choroidal vasculopathy (ipcv)
RU2657768C1 (ru) * 2017-11-23 2018-06-15 Елена Вячеславовна Волкова Способ лечения беременных с преэклампсией средней тяжести
MX2020004921A (es) 2017-11-29 2020-08-27 Hoffmann La Roche Ensayo de anticuerpo antifarmaco con supresion de interferencia del objetivo.
US12037389B2 (en) 2017-12-01 2024-07-16 Children's Hospital Medical Center Compositions for interferon blockade and methods of using same
KR20200095485A (ko) 2017-12-04 2020-08-10 라 파마슈티컬스 인코포레이티드 보체 활성의 조절인자
MX2020006113A (es) 2017-12-13 2020-08-24 Regeneron Pharma Combinaciones de anticuerpos anti-c5 y usos de las mismas.
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
US20190247560A1 (en) * 2018-02-13 2019-08-15 Gambro Lundia Ab Extracorporeal devices and methods of treating complement factor related diseases
US12404320B2 (en) 2018-05-31 2025-09-02 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) in pediatric patients
JP7577542B2 (ja) 2018-06-04 2024-11-05 アレクシオン ファーマシューティカルズ， インコーポレイテッド 小児患者における非典型溶血性尿毒症症候群（ａＨＵＳ）の治療のための抗Ｃ５抗体の用量および投与
EP3814373A1 (en) 2018-06-28 2021-05-05 Alexion Pharmaceuticals, Inc. Methods of producing anti-c5 antibodies
IL280475B2 (en) 2018-08-01 2026-04-01 Chugai Pharmaceutical Co Ltd Pharmaceutical preparation for use in the treatment or prevention of a C5-related disease and a method for treating or preventing a C5-related disease
US12098190B2 (en) 2018-09-06 2024-09-24 The Trustees Of The University Of Pennsylvania And Humanized anti-C5 antibodies and uses thereof
WO2020060987A1 (en) * 2018-09-18 2020-03-26 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use
MX2021004994A (es) 2018-10-30 2021-06-15 Alexion Pharma Inc Dosificacion subcutanea y administracion de anticuerpos anti-c5 para el tratamiento de la hemoglobinuria paroxistica nocturna (pnh).
EP3934675A2 (en) 2019-03-08 2022-01-12 RA Pharmaceuticals, Inc. Zilucoplan as deep tissue penetrating c5 inhibitor
US20230115176A1 (en) 2019-03-29 2023-04-13 Ra Pharmaceuticals, Inc. Complement Modulators and Related Methods
CA3137895A1 (en) 2019-04-24 2020-10-29 Ra Pharmaceuticals, Inc. Compositions and methods for modulating complement activity
GB2584105B (en) * 2019-05-21 2023-08-02 Argenx Bvba Methods of treating neuropathy
US12558398B2 (en) 2019-06-04 2026-02-24 Ucb Holdings, Inc. Inflammatory disease treatment with complement inhibitors
CA3144921A1 (en) 2019-07-31 2021-02-04 F. Hoffmann-La Roche Ag Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab
CN115068604A (zh) 2019-07-31 2022-09-20 豪夫迈·罗氏有限公司 通过使用抗c5抗体可伐利单抗来治疗或预防c5相关疾病的剂量和施用方案
WO2021118999A1 (en) 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Anti-c5 antibody for the treatment of neuromyelitis optica spectrum disorder
WO2021154941A1 (en) 2020-01-31 2021-08-05 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
WO2021254926A1 (en) 2020-06-16 2021-12-23 F. Hoffmann-La Roche Ag Method for determining the free antigen of an antibody in a sample
CN116194478A (zh) 2020-06-24 2023-05-30 阿雷克森制药公司 皮下（sc）施用抗c5抗体治疗补体相关病症
EP4348263A1 (en) 2021-05-28 2024-04-10 Alexion Pharmaceuticals, Inc. Methods for detecting cm-tma biomarkers
JP2024535850A (ja) 2021-09-17 2024-10-02 アルナイラム ファーマシューティカルズ， インコーポレイテッド 補体成分（Ｃ３）をサイレンシングするためのｉＲＮＡ組成物および方法
CN120035450A (zh) 2022-09-06 2025-05-23 阿雷克森制药公司 造血干细胞移植物相关血栓性微血管病（hsct-tma）患者的诊断和预后生物标志物谱
WO2025199107A1 (en) 2024-03-19 2025-09-25 Alexion Pharmaceuticals, Inc. Risk evaluation and management strategy involving patient follow-ups relating to the use or discontinuation of a complement inhibitor

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US4686100A (en) 1985-04-02 1987-08-11 The Board Of Trustees Of The Leland Stanford Junior University Method for the treatment of adult respiratory distress syndrome
AU6131086A (en) 1985-07-05 1987-01-30 Whitehead Institute For Biomedical Research Epithelial cells expressing foreign genetic material
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
DE3852304T3 (de) 1987-03-02 1999-07-01 Enzon Labs Inc., Piscataway, N.J. Organismus als Träger für "Single Chain Antibody Domain (SCAD)".
DE3852823T2 (de) 1987-09-11 1995-05-24 Hughes Howard Med Inst Transduktionsveränderte fibroblasten und ihre anwendung.
JP2914692B2 (ja) 1987-12-11 1999-07-05 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 内皮細胞の遺伝子修飾
EP0400047B1 (en) 1988-02-05 1997-04-23 Whitehead Institute For Biomedical Research Modified hepatocytes and uses therefor
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5135916A (en) 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
DE3924924A1 (de) 1989-07-27 1991-02-07 Goetze Otto Verfahren zum nachweis und/oder der quantitativen bestimmung von komplementpeptid c5a und/oder c5adesarg
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US20040010810A1 (en) 1990-01-12 2004-01-15 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9007971D0 (en) * 1990-04-09 1990-06-06 Imutran Ltd Pharmaceutical formulations
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69133557D1 (de) 1990-08-29 2007-03-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0556345B2 (en) 1990-10-31 2005-10-12 Cell Genesys, Inc. Retroviral vectors useful for gene therapy
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
US5780279A (en) 1990-12-03 1998-07-14 Genentech, Inc. Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
CA2097825A1 (en) 1990-12-06 1992-06-07 Henry C. Marsh, Jr. Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity
DE69233769D1 (de) 1991-03-01 2009-09-24 Dyax Corp Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon
WO1992022670A1 (en) 1991-06-12 1992-12-23 Genpharm International, Inc. Early detection of transgenic embryos
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2135313A1 (en) 1992-06-18 1994-01-06 Theodore Choi Methods for producing transgenic non-human animals harboring a yeast artificial chromosome
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US5508717A (en) 1992-07-28 1996-04-16 Sony Corporation Computer pointing device with dynamic sensitivity
WO1994017822A1 (en) * 1993-02-12 1994-08-18 T Cell Sciences, Inc. PULMONARY ADMINISTRATION OF sCR1 AND OTHER COMPLEMENT INHIBITORY PROTEINS
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
ES2218543T3 (es) 1994-03-07 2004-11-16 Nektar Therapeutics Procedimiento y preparacion para la administracion de insulina por via pulmonar.
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US20050287630A1 (en) 1995-04-27 2005-12-29 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE219517T1 (de) 1995-08-18 2002-07-15 Morphosys Ag Protein-/(poly)peptidbibliotheken
US20030143204A1 (en) 2001-07-27 2003-07-31 Lewis David L. Inhibition of RNA function by delivery of inhibitors to animal cells
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
AUPO755097A0 (en) 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
US7056897B2 (en) 1997-11-03 2006-06-06 The Arizona Board Of Regents Inducible expression vectors and methods of use thereof
EP1051432B1 (en) 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins
WO2000061178A1 (en) 1999-04-13 2000-10-19 Inhale Therapeutics Systems, Inc. Pulmonary administration of dry powder formulations for treating infertility
JP2002541213A (ja) 1999-04-13 2002-12-03 インヘール セラピューティック システムズ， インコーポレイテッド 不妊症の処置のための乾燥粉末処方物の肺投与
GB9910975D0 (en) 1999-05-13 1999-07-14 Univ Strathclyde Rapid dehydration of proteins
US6673346B1 (en) 1999-08-31 2004-01-06 The Regents Of The University Of Michigan Compositions and methods for the treatment of sepsis
US6794132B2 (en) 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
US6680209B1 (en) 1999-12-06 2004-01-20 Biosite, Incorporated Human antibodies as diagnostic reagents
EP1253946A2 (en) * 2000-02-10 2002-11-06 Alexion Pharmaceuticals, Inc. Mixtures of caspase inhibitors and complement inhibitors and methods of use thereof
AU2002234001B2 (en) 2000-12-05 2008-05-01 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
KR20100031769A (ko) * 2000-12-28 2010-03-24 알투스 파마슈티컬스 인코포레이티드 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
AU2002256624B2 (en) 2001-02-19 2007-12-06 Merck Patent Gmbh Method for identification of T-cell epitopes and use for preparing molecules with reduced immunogenicity
DK1401869T3 (da) 2001-06-01 2008-04-28 Biogen Idec Inc Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1
US7393648B2 (en) 2001-12-03 2008-07-01 Alexion Pharmaceuticals, Inc. Hybrid antibodies
WO2003064621A2 (en) 2002-02-01 2003-08-07 Ambion, Inc. HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
WO2003081206A2 (en) 2002-03-18 2003-10-02 Alexion Pharmaceuticals, Inc. Stratification of patient populations having or suspected of having rheumatoid arthritis
WO2003093430A2 (en) 2002-05-03 2003-11-13 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for use in preparing sirnas
US7700758B2 (en) 2002-08-12 2010-04-20 New England Biolabs, Inc. Methods and compositions relating to gene silencing
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
ES2614274T3 (es) * 2002-09-06 2017-05-30 Alexion Pharmaceuticals, Inc. Procedimiento de tratamiento de asma usando anticuerpos frente al componente de complemento C5
US9415102B2 (en) * 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
WO2004029207A2 (en) 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
US7361339B2 (en) 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
AU2004245038A1 (en) 2003-06-02 2004-12-16 Alexion Pharmaceuticals, Inc. De-immunized anti-CD3 antibody
US20050169921A1 (en) 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US20070116710A1 (en) * 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
US7803931B2 (en) * 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
NZ551308A (en) * 2004-05-14 2009-06-26 Alexion Pharma Inc Prolongation of survival of an allograft by inhibiting complement activity
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
GB0416328D0 (en) 2004-07-21 2004-08-25 Univ Cardiff Use of dry powder compositions for pulmonary delivery
MX2007014428A (es) * 2005-05-19 2008-04-21 Procter & Gamble Metodo para reducir la sepsis o el choque cardiogenico asociado a una lesion del miocardio.
EP1739078A1 (de) * 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
KR20080025174A (ko) * 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
WO2007002571A2 (en) * 2005-06-23 2007-01-04 Alexion Pharmaceuticals, Inc. Use of an anti c5 complement antibody to treat patients with sickle cell disease
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP5364870B2 (ja) 2005-08-19 2013-12-11 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
GB0518443D0 (en) * 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
JP2009508822A (ja) * 2005-09-19 2009-03-05 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 慢性腎症の処置のためのｈ因子およびその製造
FR2894145B1 (fr) * 2005-12-07 2008-10-17 Lab Francais Du Fractionnement Utilisation de facteur h du complement a titre de medicament
AU2007224250B2 (en) 2006-03-02 2012-05-03 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
ES2965283T3 (es) * 2006-03-15 2024-05-28 Alexion Pharma Inc Tratamiento de pacientes con hemoglobinuria paroxística nocturna mediante un inhibidor del complemento
US8037880B2 (en) 2006-04-07 2011-10-18 The University Of Western Ontario Dry powder inhaler
EP2013235A1 (en) * 2006-05-01 2009-01-14 Alexion Pharmaceuticals, Inc. Methods for the treatment of muscular dystrophy associated with dysferlin-deficiency
WO2008048689A2 (en) * 2006-10-20 2008-04-24 Alexion Pharmaceuticals, Inc. Methods for the treatment of muscular dystrophy associated with dysferlin-deficiency
NZ578873A (en) * 2007-03-01 2012-01-12 Wellstat Ophthalmics Corp Complement factor B analogs and uses for the treatment of complement mediated disease such as inflammation
US20110008343A1 (en) 2007-06-08 2011-01-13 Lambris John D Method Of Reducing Tissue Loss In Pancreatic Islet Cell Transplantation
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
US9447176B2 (en) 2008-11-10 2016-09-20 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
US20120022505A1 (en) 2010-07-20 2012-01-26 Bruno Dacquay Closed loop glaucoma drug delivery system

Also Published As

Publication number Publication date
JP2019203036A (ja) 2019-11-28
JP2021167362A (ja) 2021-10-21
US20160319004A1 (en) 2016-11-03
AU2009313203B2 (en) 2015-08-27
US20120225056A1 (en) 2012-09-06
HRP20230167T1 (hr) 2023-03-31
RS64039B1 (sr) 2023-04-28
US9771418B2 (en) 2017-09-26
EP2894165B1 (en) 2023-01-04
LT2894165T (lt) 2023-03-10
AU2009313203A1 (en) 2010-05-14
DK2894165T5 (da) 2024-10-14
CN102271703B (zh) 2015-09-16
NZ606825A (en) 2014-10-31
US20250092123A1 (en) 2025-03-20
PT2894165T (pt) 2023-03-17
US20170015740A1 (en) 2017-01-19
US20200071391A1 (en) 2020-03-05
US11807678B2 (en) 2023-11-07
EP3101031A1 (en) 2016-12-07
CN104940917A (zh) 2015-09-30
WO2010054403A1 (en) 2010-05-14
FI2894165T3 (fi) 2023-03-23
JP6189895B2 (ja) 2017-08-30
NZ592786A (en) 2013-02-22
EP2894165A1 (en) 2015-07-15
EP3974448A1 (en) 2022-03-30
PL2894165T3 (pl) 2023-04-17
SI2894165T1 (sl) 2023-04-28
EP2894166A1 (en) 2015-07-15
EP3121197A1 (en) 2017-01-25
JP2016196513A (ja) 2016-11-24
EP2352517A1 (en) 2011-08-10
CN109045296A (zh) 2018-12-21
US9447176B2 (en) 2016-09-20
US20160355579A1 (en) 2016-12-08
JP2012508262A (ja) 2012-04-05
CA3035432A1 (en) 2010-05-14
US20170369562A1 (en) 2017-12-28
CA2742802C (en) 2019-11-26
JP2018030882A (ja) 2018-03-01
JP2014185174A (ja) 2014-10-02
CN102271703A (zh) 2011-12-07
HUE061548T2 (hu) 2023-07-28
US20200140531A1 (en) 2020-05-07
CA2742802A1 (en) 2010-05-14
BRPI0921237A2 (pt) 2015-09-22
JP2024107240A (ja) 2024-08-08
US20160355580A1 (en) 2016-12-08
EP2352517A4 (en) 2013-01-16
JP2015155473A (ja) 2015-08-27
KR20110094029A (ko) 2011-08-19
NZ614351A (en) 2015-05-29
SMT202300082T1 (it) 2023-05-12
JP6223659B2 (ja) 2017-11-01
ES2940466T3 (es) 2023-05-08

Similar Documents

Publication Publication Date Title
DK2894165T5 (da) Fremgangsmåder og sammensætninger til behandling af komplementforbundne forstyrrelser
DK2796469T3 (da) Hidtil ukendte sammensætninger og fremgangsmåder til behandling af IgE-medierede forstyrrelser
DK2323638T3 (da) Sammensætninger og fremgangsmåder til behandling af osteoartritis
DK2766483T3 (da) Fremgangsmåder og sammensætninger til screening for og behandling af udviklingsforstyrrelser
DK2137537T3 (da) Sammensætninger og anvendelser til behandling af multipel sklerose
DK2187880T3 (da) Sammensætninger og fremgangsmåder til behandling af makuladegeneration
DK3181134T3 (da) Bifidobakterier til behandling af diabetes og relaterede tilstande
DK2350416T4 (da) Multipel rude med mindst én antirefleksbehandling og anvendelse af antirefleksbehandling i multipel rude
BRPI0920284A2 (pt) composição e método
DK2212070T3 (da) Fremgangsmåde til behandling af træ
DK3121280T3 (da) Antisense-sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf
EP2120561A4 (en) COMPOSITIONS FOR TREATING BIOFILMS, AND METHODS FOR THEIR USE
DK2252342T3 (da) Indretninger og fremgangsmåder til behandling af skadet væv
DK2365802T3 (da) Mikrokapsler af rapamycin og anvendelse til behandling af cancer
PL2356462T3 (pl) Kompozycje anty-CXCR1 oraz sposoby
DK2361090T3 (da) Sammensætninger til behandling af centralt medieret kvalme og opkastning
DK2315532T3 (da) Sammensætninger og fremgangsmåder til behandling af forstyrrelser, der er associeret med overvægtige dyr
DK2310034T3 (da) Peptider til behandling af beta-amyloidose
DK3443957T3 (da) Forbindelser og sammensætninger til behandling af cancer
BRPI0919238A2 (pt) métodos e composições para o tratamento de câncer
DK2442832T3 (da) Sammensætninger og fremgangsmåder til behandling af dissemineret sclerose
DK2437742T3 (da) Nye sammensætninger til behandling af cmt og beslægtede sygdomme
DK2482841T4 (da) Sammensætninger og fremgangsmåder til at forbedre koagulationsfaktor-viii-funktion
BRPI1007600A2 (pt) composições e métodos para tratamento de doenças cardiovasculares
BRPI1007929A2 (pt) "métodos e composições para o tratamento de neovascularização".